DEPARTMENT OF HEALTH SERVICES

Division of Medicaid Services F-01952 (01/2019)

STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH

PRIOR AUTHORIZATION DRUG ATTACHMENT FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR GIANT CELL ARTERITIS AND NEONATAL **ONSET MULTISYSTEM INFLAMMATORY DISEASE (NOMID)**

INSTRUCTIONS: Type or print clearly. Before completing this form, read the Prior Authorization Drug Attachment for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Giant Cell Arteritis and Neonatal Onset Multisystem Inflammatory Disease (NOMID) Instructions, F-01952A. Providers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization Drug Attachment for Cytokine and CAM Antagonist Drugs for Giant Cell Arteritis and NOMID form signed by the prescriber before submitting a PA request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION										
1. Name – Member (Last, First, Middle Initial)										
2. Member ID Number	3. Date of Birth – Member									
SECTION II – PRESCRIPTION INFORMATION										
4. Drug Name	5. Drug Strength									
Date Prescription Written	7. Directions for Use									
8. Name – Prescriber		National Provider Iden	ntific	r _ Droc	cribar					
o. Name – Frescriber		3. National Floride lider	itilici	-1163	CIIDCI					
10. Address – Prescriber (Street, City, State, Zip+4 Code)										
10. Address Tressinger (Chest, Chy, Chats, Ep. 1 Cods)										
11. Phone Number – Prescriber										
SECTION III – CLINICAL INFORMATION (Required for all requests.)										
12. Diagnosis Code and Description										
Note: A copy of the member's medical records must be submitted with the PA request to support the condition being treated, details regarding previous medication use, and outline the member's current treatment plan.										
SECTION III A – CLINICAL INFORMATION FOR ACTEMRA FOR GIANT CELL ARTERITIS ONLY										
13. Does the member have giant cell arteritis?				Yes		No				
<u> </u>										
14. Is the prescription written by a rheumatologist or through a rheumatology consultation?				Yes	Ц	No				
15. Is the member currently using Actemra?				Yes		No				
If yes, indicate the approximate date therapy was started.										
•										

Continued



PRIOR AUTHORIZATION DRUG ATTACHMENT FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR GIANT CELL ARTERITIS AND NEONATAL ONSET MULTISYSTEM INFLAMMATORY DISEASE (NOMID)

F-01952 (01/2019)

SECTION III B – CLINICAL INFORMATION FOR KINERET FOR NOMID ONLY									
16. Does the member have NOMID?			Yes		No				
17. Is the prescription written by a rheumatologist or through a rheumatology consultation?			Yes		No				
18. Is the member currently using Kineret?			Yes		No				
If yes, indicate the approximate date therapy was started.									
SECTION IV – AUTHORIZED SIGNATURE									
19. SIGNATURE – Prescriber	20. Date Signed								
SECTION V - ADDITIONAL INFORMATION									

^{21.} Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the product requested may be included here.